Aaron E Miller Selected Research

teriflunomide

10/2022	Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
10/2021	An updated review of teriflunomide's use in multiple sclerosis.
11/2020	Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
1/2020	Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.
8/2019	Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.
1/2019	Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
1/2018	The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
12/2017	Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience.
2/2017	Teriflunomide in multiple sclerosis: an update.
11/2016	Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aaron E Miller Research Topics

Disease

25	Multiple Sclerosis 10/2022 - 03/2002
9	Relapsing-Remitting Multiple Sclerosis 12/2019 - 03/2014
3	Infections 05/2021 - 03/2014
3	Headache (Headaches) 01/2016 - 03/2014
3	Disease Progression 07/2014 - 03/2002
2	Fatigue 05/2016 - 05/2014
2	Nausea 01/2016 - 10/2015
2	Diarrhea 01/2016 - 10/2015
1	Atrophy 10/2021
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Alopecia (Baldness) 10/2015
1	Hypertension (High Blood Pressure) 10/2015
1	Neutropenia 10/2015
1	Paresthesia (Dysesthesia) 10/2015
1	Arthralgia (Joint Pain) 10/2015
1	Respiratory Tract Infections (Respiratory Tract Infection) 10/2014
1	Mitochondrial Diseases (Mitochondrial Disease) 08/2014

Drug/Important Bio-Agent (IBA)

20	teriflunomideIBA 10/2022 - 11/2012
4	Immunologic Factors (Immunomodulators)IBA 01/2018 - 09/2014
4	Alanine Transaminase (SGPT)IBA 01/2016 - 03/2014
2	ofatumumab FDA Link 12/2019 - 01/2018
1	Amantadine (Aman)FDA LinkGeneric 01/2022
1	InterferonsIBA 01/2020
1	Oligoclonal BandsIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Fingolimod Hydrochloride (FTY720)FDA Link 11/2016
1	Dimethyl FumarateIBA 11/2016
1	CeramidesIBA 08/2014
1	MicellesIBA 08/2014
1	LipidsIBA 08/2014
1	Biomarkers (Surrogate Marker)IBA 07/2014
1	Interferon beta-1a FDA Link 05/2014
1	Pharmaceutical PreparationsIBA 03/2014
1	GadoliniumIBA 11/2012
1	Glatiramer Acetate (Copaxone)FDA Link 02/2005

Therapy/Procedure

12	Therapeutics 10/2021 - 03/2002
1	Contraindications 01/2021
1	Immunotherapy 03/2002